Actelion edges up on approvable letter

Actelion (SWX:ATLN) was up CHF1.5 to CHF41.5 ($25.60) on Tuesday. On Monday, the company received an approvable letter from the FDA for ATLN's Tracleer bosentan, an orally active endothelin receptor a...